huawei ye7

Cam Carter put LSU ahead for good with a jumper 1:08 into the third overtime and the Tigers came away with a wild 109-102 win over UCF on Sunday in the third-place game of the Greenbrier Tip-Off in White Sulphur Springs, W.Va. Carter's make sparked a 5-0 spurt for LSU (5-1), which mounted a ferocious second-half rally that began after Darius Johnson drilled a 3-pointer to put the Knights up 52-34 with 12:57 to play in regulation. UCF (4-2) got back within two in the third overtime, but it never found a way to draw even. Vyctorius Miller and Jordan Sears sealed the victory, combining for three buckets down low that gave the Tigers a 106-99 cushion with 17 seconds remaining. Carter was the late-game hero for LSU, scoring the final four points of regulation to forge a 70-70 tie. He also knocked down a go-ahead 3-pointer with 3:19 left in the first extra session to give the Tigers a 76-75 advantage. Sears gave LSU a four-point edge with a triple of his own with 2:10 to go, but the Tigers failed to stay in front, and UCF's Keyshawn Hall kept the game going by sinking two free throws with six seconds remaining to make it 82-82. Neither team led by more than three in the second overtime, with Hall again coming to the Knights' rescue. He made two layups in the final 52 seconds of the frame to knot things at 93 and send the teams to a third OT. Few could have predicted 15 minutes of extra basketball after UCF put together a 25-3 first-half run that lifted it to a 38-18 advantage with 2:12 left until the break. LSU responded with seven unanswered points, but the Knights still led comfortably, 40-25, at intermission. Sears finished with a game-high-tying 25 points to go along with nine boards, while Jalen Reed recorded a 21-point, 13-rebound double-double for the Tigers. Carter netted 20 points, Miller had 16 and Dji Bailey chipped in 14. Johnson collected 25 points, six rebounds, eight assists and five steals for UCF. Hall totaled 21 points and 10 boards, and Jordan Ivy-Curry supplied 20 points. LSU outshot UCF 43.2 percent to 40.7 percent and had narrow advantages from behind the arc (12 made shots to 10) and the free-throw line (21-18). --Field Level MediaIn Mythwrecked: Ambrosia Island, the Greek gods are queer and kind

By MARY CLARE JALONICK and MATT BROWN WASHINGTON (AP) — Pete Hegseth, President-elect Donald Trump’s nominee to lead the Defense Department, said he had a “wonderful conversation” with Maine Sen. Susan Collins on Wednesday as he pushed to win enough votes for confirmation. He said he will not back down after allegations of excessive drinking and sexual misconduct. Related Articles National Politics | Donald Trump will ring the New York Stock Exchange bell. It’ll be a first for him National Politics | The Trump and Biden teams insist they’re working hand in glove on foreign crises National Politics | ‘You don’t know what’s next.’ International students scramble ahead of Trump inauguration National Politics | Trump is threatening to raise tariffs again. Here’s how China plans to fight back National Politics | Trump won’t be able to save the struggling US beef industry Collins said after the hourlong meeting that she questioned Hegseth about the allegations amid reports of drinking and the revelation that he made a settlement payment after being accused of a sexual assault that he denies. She said she had a “good, substantive” discussion with Hegseth and “covered a wide range of topics,” including sexual assault in the military, Ukraine and NATO. But she said she would wait until a hearing, and notably a background check, to make a decision. “I asked virtually every question under the sun,” Collins told reporters as she left her office after the meeting. “I pressed him both on his position on military issues as well as the allegations against him, so I don’t think there was anything that we did not cover.” The meeting with Collins was closely watched as she is seen as more likely than most of her Republican Senate colleagues to vote against some of Trump’s Cabinet picks. She and Alaska Sen. Lisa Murkowski, a fellow moderate Republican, did not shy from opposing Trump in his first term when they wanted to do so and sometimes supported President Joe Biden’s nominees for the judicial and executive branches. And Hegseth, an infantry combat veteran and former “Fox & Friends” weekend host, is working to gain as many votes as he can as some senators have expressed concerns about his personal history and lack of management experience. “I’m certainly not going to assume anything about where the senator stands,” Hegseth said as he left Collins’ office. “This is a process that we respect and appreciate. And we hope, in time, overall, when we get through that committee and to the floor that we can earn her support.” Hegseth met with Murkowski on Tuesday. He has also been meeting repeatedly with Iowa Sen. Joni Ernst, a military veteran who has said she is a survivor of sexual assault and has spent time in the Senate working on improving how attacks are reported and prosecuted within the ranks. On Monday, Ernst said after a meeting with him that he had committed to selecting a senior official to prioritize those goals. Republicans will have a 53-49 majority next year, meaning Trump cannot lose more than three votes on any of his nominees. It is so far unclear whether Hegseth will have enough support, but Trump has stepped up his pressure on senators in the last week. “Pete is a WINNER, and there is nothing that can be done to change that!!!” Trump posted on his social media platform last week.MALAGA, Spain (AP) — No. 1-ranked Jannik Sinner won matches in singles and doubles to lead defending champion Italy to a 2-1 comeback victory over Argentina on Thursday, earning a return trip to the Davis Cup semifinals. “I’m here trying to do the best I can in the singles,” Sinner said. “If they put me on the court in doubles, I’ll also try my best.” On Saturday, Italy will face Australia in a rematch of last year's final, but this time it will only be for a chance to play for the championship. Australia eliminated the U.S. 2-1 earlier Thursday to reach the final four at the team competition for the third consecutive year. The other semifinal, to be contested Friday, is the Netherlands against Germany. The Dutch got past Rafael Nadal and Spain in the quarterfinals earlier in the week, sending the 22-time Grand Slam champion into retirement. Italy fell behind 1-0 in the quarterfinals when Argentina’s Francisco Cerúndolo defeated Lorenzo Musetti 6-4, 6-1 on an indoor hard court at the Palacio de Deportes Jose Maria Martina Carpena in southern Spain. But then in stepped Sinner, whose season already includes two Grand Slam trophies — at the Australian Open and U.S. Open — plus the title at the ATP Finals last weekend in Turin, Italy. First he overwhelmed Sebastián Báez 6-2, 6-1. Then Sinner teamed with 2021 Wimbledon runner-up Matteo Berrettini in the deciding doubles match to win 6-4, 7-5 against Andres Molteni and Maximo Gonzalez. “He carried me today,” Sinner said about Berrettini. After arriving late to Malaga from Turin, Sinner did not get a chance to practice on the Davis Cup competition court before taking on Báez and stretching his streak to 22 sets won in a row. “In three minutes, he was perfectly comfortable on court,” Italy captain Filippo Volandri said. “He’s a special one.” Volandri swapped out his original doubles team, Simone Bolelli and Andrea Vavassori, for Sinner and Berrettini, and the change paid dividends. Australia, the Davis Cup runner-up the last two years, advanced when Matt Ebden and Jordan Thompson beat the surprise, last-minute American pairing of Ben Shelton and Tommy Paul 6-4, 6-4 in that quarterfinal's deciding doubles match. The Shelton-Paul substitution for Paris Olympics silver medalists Austin Krajicek and Rajeev Ram was announced about 15 minutes before the doubles match began. Ebden and John Peers beat Krajicek and Ram in the Summer Games final in August. The Australians broke once in each set of the doubles. In the second, they stole one of Shelton’s service games on the fourth break opportunity when Ebden’s overhead smash made it 5-4. Thompson then served out the victory, closing it with a service winner before chest-bumping Ebden. The 21st-ranked Shelton made his Davis Cup debut earlier Thursday in singles against 77th-ranked Thanasi Kokkinakis, who emerged from a tight-as-can-be tiebreaker by saving four match points and eventually converting his seventh to win 6-1, 4-6, 7-6 (14). No. 4 Taylor Fritz , the U.S. Open runner-up, then pulled the Americans even with a far more straightforward victory over No. 9 Alex de Minaur , 6-3, 6-4. When their match finally ended, on a backhand by Shelton that landed long, Kokkinakis dropped onto his back and pounded his chest. After he rose, he threw a ball into the stands, then walked over to Australia’s sideline, spiked his racket and yelled, before hugging captain Lleyton Hewitt. “I don’t know if I’ve been that pumped up in my life. I wanted that for my team,” said Kokkinakis, who won the 2022 Australian Open men’s doubles title with Nick Kyrgios. “It could have gone either way, but I kept my nerve.” AP tennis: https://apnews.com/hub/tennis

Israel launches new airstrikes on Lebanon as leaders draw closer to ceasefire with Hezbollah

Shumate's 22 help McNeese beat Div. III-LeTourneau 103-69None'Crucial week': make-or-break plastic pollution treaty talks begin

The San Francisco 49ers will be missing two of their best players in their must-win matchup against the Green Bay Packers Sunday. Brocky Purdy and Nick Bosa have officially been ruled out, which means the 49ers will be missing a star on both sides of the ball. More News: Latest on Cowboys' CeeDee Lamb, Daron Bland, Zach Martin Injuries Purdy is dealing with a shoulder injury serious enough to sideline him in arguably the most important game of the season. The 49ers have a slim chance to reach the playoffs and have to win most, if not all, of their upcoming games in order to stay in contention. Backup Brandon Allen will get the start against Green Bay, head coach Kyle Shanahan announced. As for the severity of Purdy's injury, Shanahan's comments weren't quite clear about a timeline for the quarterback's return. "I don't wanna say there's long term concern," Shanahan said. "We got the MRI on Monday, we thought he just needed some rest. We really weren't concerned about him not being good this week, but when he started [practicing] on Thursday it surprised us and surprised him how [his shoulder] felt." Bosa is dealing with an oblique injury that was made worse by the defensive end's efforts in the 49ers' rivalry matchup with the Seattle Seahawks last week. On Thursday, Bosa said he was making progress with his recovery but it was too soon to tell whether he'd take the field Sunday. It's now confirmed that both Purdy and Bosa won't suit up for Sunday's game against the Packers. Last season, the 49ers reached the Super Bowl. Though San Francisco ultimately fell short to the Kansas City Chiefs, the 49ers were still predicted to have another great season in 2024. By Week 1, it was evident the season had already taken a turn for the worst. The 49ers announced just minutes before kickoff that star running back Christian McCaffrey wouldn't be playing due to Achilles tendinitis. A few weeks later McCaffrey's injury saga continued as he went to see a specialist in Germany, indicating the severity of his ailment. The 49ers also battled injuries all season long, but lost star wide receiver Brandon Aiyuk after he tore his ACL/MCL in Week 7. The tale of the 2024 season continues with the latest stars sidelined by injury. With Allen under center on Sunday, it doesn't bode much confidence that the 49ers will get back in the win column. The nightmare season continues for the 49ers. For more on the NFL , head to Newsweek Sports .Lately, when I find myself feeling a little too calm about things, I’ve taken to reading the Reddit subreddit r/singularity to help swing my equilibrium back to its natural state of intense panic. This is a place where activity has flourished in recent months, as community members feverishly discuss the day’s ever-increasing developments in artificial intelligence and casually argue about the date they expect computers to officially exceed all human control. “AGI by the end of 2025” predicted a top ranking post on the subreddit this week, referencing the stage of singularity when “artificial general intelligence” – the point at which computers can perform any intellectual task that a human can – is reached. The excitement was caused by OpenAI’s announcement that its o3 system can now reason through maths, science and computer programming problems, which are three things I definitely can’t do. We had the chance to give computers less control, and instead we gave them more. Credit: iStock It got me thinking: we should have just let the Y2K bug win, hey? There we were, exactly 25 years ago, gifted with a date glitch that would’ve sent us warmly back to the 1900s, when life was simple and butter was churned in the backyard. But instead we panicked, worried that nuclear plants would melt down, planes would fall out of the sky, ATMs would erase all our savings, and like Bill Pullman in Independence Day we chose to fight. Now, 25 years on and with robot overlords breathing down our necks, it feels like a fork-in-the-road moment where we Robert Frosted the wrong way. We had the chance to give computers less control, and instead we gave them more. Dummy move! Perhaps because I’d just turned legal drinking age, or perhaps because I was watching Buffy religiously instead of following the news, I don’t remember feeling too concerned about the Y2K bug. What did I care if computers thought it was 1900 instead of 2000? Life across those 100 years wasn’t that different. In 1999, I still walked everywhere; I still did school exams in pencil; I still developed 35mm film negatives for my day job like Thomas Edison in his laboratory. Computers might’ve been around, but they weren’t such a part of our lives as they are now. I’d go whole days without touching one sometimes, except to play Grim Fandango . We were so close, as this archival shot from the film Time Bomb Y2K shows. Not to get all John Lennon, but imagine there were no computers. I wouldn’t miss them. I’d be sitting by a river bank right now, writing this column in salmon blood with my index finger. We’d all be so close to nature we could taste it, like the kid from Into the Wild . Maybe we’d die eating berries, but we’d live eating berries, too. If computers had died in 1999, we wouldn’t have social media either, the worst experiment in humankind since lobotomies. Instead we’d just have polite conversation with whoever was in our vicinity and/or crushing loneliness, both preferable options. If Y2K had happened, industry would be thriving too. No computers means no factory closures means no Donald Trump, it’s a simple equation. And not just manual industries, but creative ones too. If computers had died, music might still be a viable artistic career. I know this because in 1999 it would take me four days to download one Talib Kweli song, whereas today I just skimmed through his full life’s work during a toilet break. No one should have such carefree access to an artist’s entire life work, especially during a bowel movement. It’s not right. Maps. Street directories. The Yellow Pages. Privacy. Look at all the things we lost because, 25 years ago, we chose to save computers instead. A worthwhile exchange? I don’t know, maps were fun to fold. You can’t fold a GPS, you can just yell at its ignorant directions. “But what about the hospitals?” you’re probably saying. “Hospitals need computers.” Yes, I’m sure computers have saved more lives than the cast of Bondi Rescue , and the result is overpopulation. To paraphrase Paris Hilton, sometimes you just have to leave the party. The people of 1900, aprons splattered in freshly churned butter, understood this. As you can see, the Y2K bug got an unnecessarily bad rap in 1999. The good news is that we have another chance to get it right in 2038, when at 03:14:08 UTC on 19 January 2038, computer systems running on Unix time will suddenly revert to 20:45:52 on Friday, 13 December 1901. It’s called the Year 2038 Problem , which isn’t as catchy as Y2K, but it’ll do. Butter churning, here I come. To read more from Spectrum , visit our page here . Get a weekly wrap of views that will challenge, champion and inform your own. Sign up for our Opinion newsletter .

Apple iOS 18 Hearing Aids: Are AirPods Pro 2 Headsets Sufficient Alternatives?Leicester City manager Ruud van Nistelrooy wants to offload attacker in January

LONDON, Nov. 21, 2024 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the European debut of its GenScript Biotech Global Forum in London, UK. Since its inaugural session at the J.P. Morgan Healthcare Conference in San Francisco in 2020, the forum has become a significant platform for advancing cell and gene therapy (CGT). This year's move to Europe underscores GenScript's commitment to driving the global CGT innovation and fostering international collaboration. "Putting patients first" is the underlying principle driving progress in the pharmaceutical industry and the inspiration behind this year's forum. "All our efforts in creating this platform for open dialogue and international collaboration in the CGT industry ultimately aim to address patient needs," said Jesse Chen, VP of Government Affairs and Corporate Communications at GenScript, in a pre-event interview. The forum brought together global thought leaders from academia, industry, and investment sectors in CGT to explore the theme "Unlock the Full Potential of Cell and Gene Therapies." Discussions focused on the latest breakthroughs, technological innovations, and future trends, offering multi-dimensional perspectives on advancing the CGT industry to benefit more patients. The forum was moderated by Dr. Shawn Wu, President of European Division at GenScript. Sherry Shao, Rotating CEO of GenScript, delivered the opening remarks, emphasizing: "Every step forward in CGT, every innovation, is ultimately about serving patients better." She reaffirmed GenScript's commitment to driving innovation in CGT and collaborating with global partners to bring life-changing therapies to more patients worldwide. The forum featured two keynote sessions with distinguished speakers: Dr. Miguel Forte, President of the International Society for Cell & Gene Therapy (ISCT), ARM Board Member, and CEO of Kiji Therapeutics, and Dr. James Wilson, a pioneer in gene therapy and President & CEO of Gemma Biotherapeutics (GEMMABio); Founder and Advisor of Scout Bio, Passage Bio, iECURE; Executive Chair at Franklin Biolabs. Their thought-provoking presentations not only deepened attendees' understanding of the field but also offered valuable insights into the future of cell and gene therapy (CGT). Dr. Forte's delivered a keynote titled "Status and Expectations for Cell and Gene Therapy in 2024 and Beyond," focused on the transformative potential of cell therapy. He delved into gene editing, in vivo therapies, and the challenges and opportunities associated with regulatory approval. He emphasized the importance of understanding the long-term nature of cell therapy development and the significance of global collaboration. Dr. Wilson's keynote, "The Case for Rare Diseases in Genetic Medicine Development," He emphasized the importance of gene therapy for rare diseases and elaborated on the commercialization challenges of gene therapy products and discussed issues encountered in clinical development, such as technological shortcomings, the complexity of clinical trials, and production challenges. Dr. Wilson also emphasized the importance of patient advocacy and social media in promoting drug accessibility and raising public awareness. Additionally, he highlighted the need to focus on reimbursement mechanisms and achieve a balance between innovation and the resource utilization of health authorities. In addition to the compelling keynote speeches, the forum featured a range of dynamic interactive sessions, including three roundtable discussions and a fireside chat. These sessions attracted significant attention, offering lively debates and actionable insights that resonated with the audience. The success of CAR-T therapies in hematologic malignancies has revealed the vast potential of cell therapies. Now, the focus is on extending these breakthroughs to broader patient populations, including those with solid tumors and autoimmune diseases, which have become a shared goal across the industry. During the "Technology Innovation and Breakthroughs in Cell Therapy" roundtable, Mr. Stephen Hansen, Director of Biopharma Intelligence at BioCentury, moderated a vibrant discussion featuring leaders such as Dr. Ying Huang, CEO of Legend Biotech, Dr. Reagan Jarvis, CEO and Co-founder of Anocca, Dr. Pascal Touchon, Chairman of the Board at Atara Biotherapeutics, Mr. Jason Foster, CEO and Executive Director of Ori Biotech, and Dr. Biao Zheng, CEO of BRL Medicine. They approached the topic from the patient's perspective, highlighting the exceptional efficacy of CAR-T therapy. The experts also shared promising clinical data on the use of CAR-T drugs for autoimmune diseases and expressed high hopes for their future development. They emphasized that developing more patient-friendly, user-friendly CAR-T therapies is critical for increasing patient acceptance. Additionally, expanding production capacity, improving product accessibility, and ensuring product safety are urgent priorities. Collaboration with medical centers is key to developing commercially viable products. As innovative therapies continue to be researched, the potential applications of CAR-T therapy will be further unlocked, offering patients more treatment options. Driven by technological breakthroughs, significant progress has been made in gene therapy and mRNA vaccine fields, with applications expanding rapidly. However, the production of these therapies is complex, particularly when it comes to the choice, production, and optimization of delivery vectors, which have a profound impact on their development. In the roundtable discussion on "Progress in Gene Therapy and mRNA Vaccine," hosted by Ms. Kristina Cornish, Partner at Pinsent Masons, London & European and UK Patent Attorney, leading researchers including Mr. Deividas Pazeraitis, Senior Scientist at AstraZeneca, Dr. Karim Benabdellah, Principal Investigator at GENYO, Dr. Maelle Quere, Scientist at Sanofi, Dr. Vincenzo Di Cerbo, Lead Technical Scientist at Cell and Gene Therapy Catapult, and Dr. Lumeng Ye, Director of Novel therapeutic materials at GenScript; all agreed that long-term delivery efficiency and technological bottlenecks remain key challenges in translating innovations into clinical applications. The discussion focused on the technological trends and innovative developments in the clinical applications of gene editing, the topics cover the selection of viral vectors (VP), non-viral vectors (NVP), lipid nanoparticles (LNP), and virus-like particles (VLP) in different application areas, the innovative developments in gene therapy and mRNA vaccines, as well as an analysis of the advantages and disadvantages of mRNA vaccines compared to traditional vaccines, along with development trends and application prospects. They also provided a comprehensive review of the progress from technological innovation to clinical application in this field and unanimously agreed that long-term delivery technology and in vitro cell line technology remain key challenges. The development process for CGT is highly complex and personalized, and these characteristics are seen as major challenges to the continuous supply of these therapies. In the subsequent roundtable discussion on "CMC Challenges with Developing & Manufacturing Cell and Gene Therapies," led by Dr. Qingyu Cao, Senior Director & head of European Business Development at ProBio, and panelists are Dr. Jim Faulkner, CEO of JDB BioConsulting, Mr. Arindam Mitra, CMC Director at Leucid Bio, Dr. Dima Al-hadithi, Director at Minaret Consulting Limited, and Ms. Ming Ewe, CEO of Smarter Biotech Solutions, engaged in lively discussions on key issues such as production process standardization, quality control, and viral vector production. The discussion presented practical strategies and solutions, providing important references for the widespread application of CGT. The experts emphasized the need for early planning of CMC and regulatory strategies in the context of accelerated approval processes, ensuring that product development and quality control can proceed in parallel. They also highlighted the importance of selecting the right CDMO partners to support full collaboration. Furthermore, they suggested that efforts should begin early in the R&D phase, with active communication with regulatory agencies to enhance the understanding of new technologies and methods, and a clear supply chain map should be created to ensure stable supply. Regarding future trends, the experts believe that AI technology will play a key role in optimizing gene therapy design, improving production efficiency, and advancing automation processes. They are confident that, with ongoing technological advancements and increasing market competition, the price of CGT therapies will gradually decrease, making them a widely accessible treatment option. R&D and manufacturing in the cell and gene therapy field require substantial financial investment, with long return cycles, making funding pressure a key constraint on industry growth. In the closing fireside chat, "Navigating the Future of CGT: Insights from Investors," was moderated by Dr. Kelly Shi, Senior VP & Research Analys at Jefferies LLC, Dr. Josh Resnick, Senior Managing Director at RA Capital Management, and Mr. Ping Shek, Managing Director at Stifel's Investment Banking Division, discussed the investment landscape for CGT. The speakers shared their investment insights in the CGT field, reviewing the evolution of the sector from its early boom to the current adjustment phase. When discussing investment strategies, the participants highlighted key considerations such as addressing patient needs, reducing uncertainty in research and development as well as manufacturing, and increasing commercialization success rates. They also emphasized the need for continued innovation in reducing manufacturing costs. Regarding the investment trend in CGT, despite market fluctuations, signs of recovery began to emerge in 2023, indicating a positive outlook for future capital inflows. Currently, investment behavior is becoming more cautious, and the market is steadily moving toward normalization. Furthermore, the evolving regulatory environment and changes in reimbursement policies have had a profound impact on investment decisions. Addressing infrastructure development and therapy accessibility is viewed as a core driver for the sustained growth of the industry. The GenScript Biotech Global Forum concluded successfully with engaging discussions from experts and scholars. This event brought together global leaders from the biopharmaceutical industry, who shared valuable experiences and unique insights, injecting fresh momentum into the continued development and innovation of the global cell and gene therapy sector. Moving forward, GenScript Biotech remains committed to building more open and inclusive collaboration platforms to drive innovation and progress in the field of cell and gene therapy. As an annual event, the GenScript Global Forum will continue to uphold its core focus of "patient-centered" goals, advancing scientific innovation and market applications in cell and gene therapies, bringing greater hope for a healthier global future. About GenScript Biotech Corporation GenScript Biotech Corporation (HK.1548) is a world leader in technologies and services for life science R&D and manufacture. Built upon its solid DNA synthesis technology, the company comprises four major business units: a life-science services and products business unit, a biologics contract development and manufacturing organization (CDMO) business unit, an industrial synthetic products business unit, and Cell Therapy Business Unit. GenScript accelerates scientific discovery and therapeutic breakthrough with its customers. Since its founding in New Jersey, USA in 2002, GenScript has expanded its operations to serve more than 200,000 customers across 100 countries with a dedicated team of 5060 employees. As of June 30, 2024, over 100,000 peer-reviewed journal articles worldwide had cited GenScript 's services and products. Guided by its mission to make people and nature healthier through biotechnology, GenScript strives to become the most trustworthy biotech company in the world. For more information, please visit GenScript Biotech's official website https://www.genscript.com View original content: https://www.prnewswire.com/news-releases/the-genscript-biotech-global-forum-makes-a-strong-debut-in-europe-highlighting-breakthroughs-in-cell-and-gene-therapy-development-302313220.html SOURCE GenScript Biotech Corporation

3 ruled out, 2 others questionable for Eagles vs. Rams on Sunday Night Football | Sporting NewsIndia to play Champions Trophy games at neutral venueBad Bunny announces a new album, 'Debí Tirar Más Fotos'

ALBANY — New Yorkers could get “Inflation Refund” checks of up to $500 from the state government next year under a proposal from Gov. Kathy Hochul. The plan, which must first be approved by state lawmakers, would send out one-time payments of $300 to people who earn less than $150,000 and $500 to families making less than $300,000. Hochul is floating the idea as part of her agenda for the upcoming state legislative session that begins in January. Payments would start going out to residents in the fall if the plan makes it througha the Legislature. The proposal would be funded by a pool of excess sales tax revenues that have been mostly generated through inflation’s effect on consumer goods, according to Hochul’s office. “I believe that this extra inflation-driven sales tax revenue shouldn’t be spent by the state. It’s your money, and it should be back in your pockets,” the governor said. The $3 billion in payments would go out to about 8.6 million people statewide, including approximately 208,000 residents in the Mohawk Valley. New Yorkers who filed tax returns would be eligible for the program. Not everyone is a fan of the governor’s plan. State Sen. Joseph A. Griffo, R-53, Rome, panned the proposal, saying it doesn’t provide meaningful relief to taxpayers. “People deserve a break all the time, not just one time,” Griffo said of the proposed “Inflation Refund.” “New Yorkers continue to feel the effects of inflation and other economic pressures that make it difficult for them to afford necessities such as groceries, heat and housing,” Griffo said. “While I am pleased that the governor recognizes that this is a problem, I am concerned that her proposal — an attempt to win popularity because of low poll numbers — does not go far enough.” “Instead of insufficient one-time payments, we should look for ways to permanently reduce the costs overburdening New Yorkers, including enhancing and expanding the School Tax Relief (STAR) program and making permanent cuts to New York’s taxes and fees,” the state senator added. “This approach, as opposed to political posturing, is how we can make New York more affordable now and for future generations.” The “Inflation Refund” is the first of Hochul’s proposals in her upcoming 2025 State of the State message in January. “My agenda for the coming year will be laser-focused on putting money back in your pockets, and that starts with proposing Inflation Refund checks of up to $500 to help millions of hard-working New Yorkers,” Hochul said. “It’s simple: the cost of living is still too damn high, and New Yorkers deserve a break.” “Governor Hochul’s proposed inflation refund is a critical step in addressing the affordability crisis impacting so many New Yorkers,” said Grace Bonilla, president and CEO of the United Way of New York City. “As highlighted in our True Cost of Living report, 50% of New Yorkers struggle to make ends meet. Rising rents, utility bills, grocery prices and child care costs are pushing families to their breaking point. We witness these challenges every day and this refund is the type of direct investment needed to provide relief.”

Democrats plan to elect new party leader just days after Trump's inaugurationTotal S.A. stock touches 52-week low at $58.45 amid market shiftsMarjorie Taylor Greene Calls NPR 'Democrat Propaganda,' Threatens To Slash Its Funding

Liverpool punish rivals’ errors with dominant win over Leicester to stretch lead